306 related articles for article (PubMed ID: 36230805)
41. Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN).
Galot R; Machiels JH
Cancer Treat Rev; 2020 Apr; 85():101992. PubMed ID: 32092618
[TBL] [Abstract][Full Text] [Related]
42. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
43. DNA methylation signatures in circulating cell-free DNA as biomarkers for the early detection of cancer.
Wang J; Han X; Sun Y
Sci China Life Sci; 2017 Apr; 60(4):356-362. PubMed ID: 28063009
[TBL] [Abstract][Full Text] [Related]
44. Liquid Biopsy in Head and Neck Cancer: Its Present State and Future Role in Africa.
Temilola DO; Adeola HA; Grobbelaar J; Chetty M
Cells; 2023 Nov; 12(22):. PubMed ID: 37998398
[TBL] [Abstract][Full Text] [Related]
45. Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma.
Zhang Y; Liu Z; Ji K; Li X; Wang C; Ren Z; Liu Y; Chen X; Han X; Meng L; Li L; Li Z
Front Mol Biosci; 2021; 8():736330. PubMed ID: 34660697
[TBL] [Abstract][Full Text] [Related]
46. Detection of Cell Types Contributing to Cancer From Circulating, Cell-Free Methylated DNA.
Barefoot ME; Loyfer N; Kiliti AJ; McDeed AP; Kaplan T; Wellstein A
Front Genet; 2021; 12():671057. PubMed ID: 34386036
[TBL] [Abstract][Full Text] [Related]
47. Circulating Non-Coding RNAs in Head and Neck Cancer: Roles in Diagnosis, Prognosis, and Therapy Monitoring.
Diez-Fraile A; Ceulaer J; Derpoorter C; Spaas C; Backer T; Lamoral P; Abeloos J; Lammens T
Cells; 2020 Dec; 10(1):. PubMed ID: 33396240
[TBL] [Abstract][Full Text] [Related]
48. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.
Zhang X; Ju S; Wang X; Cong H
Clin Exp Med; 2019 Aug; 19(3):271-279. PubMed ID: 31190187
[TBL] [Abstract][Full Text] [Related]
49. Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas.
Braig D; Runkel A; Eisenhardt AE; Schmid A; Zeller J; Pauli T; Lausch U; Wehrle J; Bronsert P; Jung M; Kiefer J; Boerries M; Eisenhardt SU
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142126
[TBL] [Abstract][Full Text] [Related]
50. Unveiling targeted cell-free DNA methylation regions through paired methylome analysis of tumor and normal tissues.
Li T; Patel KB; Yu X; Yao S; Wang L; Chung CH; Wang X
bioRxiv; 2023 Jun; ():. PubMed ID: 37425680
[TBL] [Abstract][Full Text] [Related]
51. Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer.
Chen Q; Zhang ZH; Wang S; Lang JH
Onco Targets Ther; 2019; 12():11517-11530. PubMed ID: 31920340
[TBL] [Abstract][Full Text] [Related]
52. The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring.
Openshaw MR; Page K; Fernandez-Garcia D; Guttery D; Shaw JA
Expert Rev Mol Diagn; 2016 Jul; 16(7):751-5. PubMed ID: 27144417
[TBL] [Abstract][Full Text] [Related]
53. Head and neck cancer: searching for genomic and epigenetic biomarkers in body fluids - the state of art.
Ribeiro IP; de Melo JB; Carreira IM
Mol Cytogenet; 2019; 12():33. PubMed ID: 31333762
[TBL] [Abstract][Full Text] [Related]
54. Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy.
Zwirner K; Hilke FJ; Demidov G; Ossowski S; Gani C; Rieß O; Zips D; Welz S; Schroeder C
Radiother Oncol; 2018 Dec; 129(3):575-581. PubMed ID: 30097252
[TBL] [Abstract][Full Text] [Related]
55. Cell-Free DNA Methylation Profiling Analysis-Technologies and Bioinformatics.
Huang J; Wang L
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31698791
[TBL] [Abstract][Full Text] [Related]
56. Advanced liquid biopsy technologies for circulating biomarker detection.
Soda N; Rehm BHA; Sonar P; Nguyen NT; Shiddiky MJA
J Mater Chem B; 2019 Nov; 7(43):6670-6704. PubMed ID: 31646316
[TBL] [Abstract][Full Text] [Related]
57. A Novel Tissue-Free Method to Estimate Tumor-Derived Cell-Free DNA Quantity Using Tumor Methylation Patterns.
Melton CA; Freese P; Zhou Y; Shenoy A; Bagaria S; Chang C; Kuo CC; Scott E; Srinivasan S; Cann G; Roychowdhury-Saha M; Chang PY; Singh AH
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201510
[TBL] [Abstract][Full Text] [Related]
58. Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook.
Lianidou E
Mol Oncol; 2021 Jun; 15(6):1683-1700. PubMed ID: 33942482
[TBL] [Abstract][Full Text] [Related]
59. Circulating tumor DNA - Current state of play and future perspectives.
De Rubis G; Krishnan SR; Bebawy M
Pharmacol Res; 2018 Oct; 136():35-44. PubMed ID: 30142423
[TBL] [Abstract][Full Text] [Related]
60. Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients.
Porter A; Natsuhara M; Daniels GA; Patel SP; Sacco AG; Bykowski J; Banks KC; Cohen EEW
Transl Cancer Res; 2020 Jan; 9(1):203-209. PubMed ID: 35117174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
